Pim-3 as a potential predictor of chemoradiotherapy resistance in locally advanced rectal cancer patients.

ABSTRACT: Approximately 30% of locally advanced rectal cancer patients might not benefit from chemoradiotherapy; however, the response to neoadjuvant chemoradiotherapy in these cases is difficult to predict. Pim-3 is a member of the provirus integration site for a moloney murine leukemia virus family of proteins that contributes to cell proliferation, survival, and chemotherapy resistance. Therefore, the relationship between Pim-3 expression and response to neoadjuvant chemoradiotherapy in rectal cancer patients is important to evaluate. 175 rectal cancer patients who underwent neoadjuvant treatment enrolled in this study. The relationship between Pim-3 expression on immunohistochemical analysis of rectal cancer tissue, which was obtained before treatment, the response to chemoradiotherapy and survi

SUBMITTER: Zhang RX 

PROVIDER: S-EPMC5700084 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature